18F-FDOPA PET/CT in Oncology: Procedural Guideline by the KoreanSociety of Nuclear Medicine
10.1007/s13139-024-00899-6
- Author:
Yong-Jin PARK
1
;
Joon Ho CHOI
;
Hyunjong LEE
;
Seung Hwan MOON
;
Inki LEE
;
Joohee LEE
;
Jang YOO
;
Joon Young CHOI
;
Author Information
1. Department of Nuclear Medicine, Ajou University Medical Center, Ajou University School of Medicine, Suwon, Republic of Korea
- Publication Type:GUIDELINES
- From:Nuclear Medicine and Molecular Imaging
2025;59(1):41-49
- CountryRepublic of Korea
- Language:English
-
Abstract:
This guideline outlines the use of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on inter-national standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effec-tive application of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma. It also addresses the use of premedication with carbidopa, fasting protocols, and optimal imaging techniques. The aim is to assist nuclear medicine professionals in delivering precise diagnoses, improving patient outcomes, and accommodating evolving medical knowl-edge and technology. This comprehensive document serves as a practical resource to enhance the accuracy, quality, and safety of 3,4-dihydroxy-6- 18F-fluoro-L-phenylalanine positron emission tomography / computed tomography in oncology.
